Harald Busse1, Josephin Otto1, Alexander Schaudinn1, Nicolas Linder1, Simone Mucha1, Nikita Garnov1, Minh Do2, Roman Ganzer2, Jens-Uwe Stolzenburg2, Lars-Christian Horn3, Thomas Kahn1, and Michael Moche1
1Diagnostic and Interventional Radiology Department, Leipzig University Hospital, Leipzig, Germany, 2Urology Department, Leipzig University Hospital, Leipzig, Germany, 3Institute of Pathology, University of Leipzig, Leipzig, Germany
Multiparametric MRI has been
shown to improve the detection and localization of prostate cancer and is therefore
ideally suited for targeting as well. While biopsy guidance in an MRI system typically
requires more efforts and time (30‑120 min) than under ultrasound imaging, MRI provides
unparalleled contrast of the prostate substructures. Diagnostic detection rates
show large variability between patient groups and sites (about 10-60%). With a custom-made
navigation option for a commercial device, any intraprocedural MRI data can be
used for stereotactic real-time biopsy targeting. This work presents navigation
features, indications and clinical biopsy results for a total of 75 patients.
